Influence of the implementation of an interdisciplinary tumorconference of integrative oncologie on the treatment of oncological patients

• Conditions: C18; C20; C50; C51; C52; C55; C56; C61; C90; C91

• Registration Number: DRKS00003294
• Lead Sponsor: Tumorzentrum Freiburg CCCF

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10-10
• Study Completion: 2013-04-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 996

Inclusion Criteria

In the cross-sectional study all patients are included who have a tumor as a secure main diagnostic and have been in an organ center (breast center, gynecologic oncology, intestine center, prostate center, or leukemia center) at the University Hospital of Freiburg, and had 8 weeks before a treatment decision or were previously presented in a tumor board. To get sufficient homogeneity after stratification into the groups , only patients are interviewed who have received the following diagnoses: colorectal cancer, prostate cancer, breast cancer, gynecological tumors or leukemia.
In these highly prevalent tumor entities is a long-term therapy possible because they have a longer survival time. This ensures that the patients could benefit from the introduction of integrative oncology tumor boards.

In the longitudinal study cancer patients are included who will be presented in the integrative oncology tumor board because they would like to have a complementary medical treatment decision or need a second opinion or need a recommendation as the therapeutic treatment must be changed.
This can be oncology patients from the outpatient clinic for naturopathy or oncology patients from the outpatient departments or other cancer patients from the wards of University Hospital in Freiburg.

Exclusion Criteria

Excluded are patients who are not powerful in the use of the German language or for other reasons are unable to complete the questionnaires.
All patients who are younger than 18 years.
Lack of consent.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The first main objective of the study is to measure the effect of the establishment of an integrative oncology tumor board on the patients' satisfaction concerning the:<br>a) medical care provided by the University Hospital Freiburg (UKF)<br>b) complementary medical care at the UKF<br>c) involvement in decision making<br><br>The second main objective is measure the influence of the establishment of an integrative oncology tumor board on the general information of patients about complementary medicine and the use of complementary medicine.<br>All measurement are done with questionnaires.<br>First endpoint is after 5 months, the second after 16 months.

Secondary Outcome Measures

Name	Time	Method
Of further interest are<br>a.) the typical sources of information for complementary medicine<br>b.) its impact on communication with patients about the existing tumor boards<br>c.) change of use of complementary medicine<br>In the long term, a comparison is being considered in survival time, which can be done in a Follow up study.<br>Regardless of the introduction of integrative oncology tumor board the influence of various factors like the patient's gender, age, their education, the tumor entity and stage of the tumor on the use of complementary medicine will be examined.